Bristol-Myers Squibb Co (NYSE:BMY) Shares Bought by Welch & Forbes LLC

Welch & Forbes LLC grew its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 3.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 218,664 shares of the biopharmaceutical company’s stock after purchasing an additional 6,610 shares during the period. Welch & Forbes LLC’s holdings in Bristol-Myers Squibb were worth $14,036,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the company. Psagot Investment House Ltd. boosted its position in shares of Bristol-Myers Squibb by 4.6% in the 3rd quarter. Psagot Investment House Ltd. now owns 4,038 shares of the biopharmaceutical company’s stock valued at $205,000 after purchasing an additional 178 shares during the period. Archford Capital Strategies LLC boosted its position in shares of Bristol-Myers Squibb by 0.8% in the 4th quarter. Archford Capital Strategies LLC now owns 23,810 shares of the biopharmaceutical company’s stock valued at $1,528,000 after purchasing an additional 189 shares during the period. Weaver Consulting Group boosted its position in shares of Bristol-Myers Squibb by 3.5% in the 3rd quarter. Weaver Consulting Group now owns 5,906 shares of the biopharmaceutical company’s stock valued at $263,000 after purchasing an additional 200 shares during the period. Community Bank of Raymore boosted its position in shares of Bristol-Myers Squibb by 2.6% in the 4th quarter. Community Bank of Raymore now owns 8,005 shares of the biopharmaceutical company’s stock valued at $514,000 after purchasing an additional 200 shares during the period. Finally, Roof Eidam & Maycock ADV boosted its position in shares of Bristol-Myers Squibb by 1.7% in the 4th quarter. Roof Eidam & Maycock ADV now owns 11,836 shares of the biopharmaceutical company’s stock valued at $760,000 after purchasing an additional 200 shares during the period. 83.02% of the stock is currently owned by institutional investors.

A number of equities analysts recently weighed in on BMY shares. ValuEngine upgraded Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a research report on Tuesday, November 19th. UBS Group increased their price target on Bristol-Myers Squibb from $51.00 to $53.00 and gave the company a “neutral” rating in a research report on Wednesday, October 23rd. Citigroup upgraded Bristol-Myers Squibb from a “neutral” rating to a “buy” rating and set a $73.00 price target for the company in a research report on Monday, January 6th. Wolfe Research set a $66.00 price target on Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Friday, November 1st. Finally, Argus upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $80.00 price target for the company in a research report on Friday, December 13th. One analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $61.69.

NYSE BMY traded up $0.28 during trading on Friday, reaching $67.06. 4,024,267 shares of the company’s stock were exchanged, compared to its average volume of 15,257,604. Bristol-Myers Squibb Co has a fifty-two week low of $42.48 and a fifty-two week high of $67.09. The firm has a market capitalization of $108.25 billion, a PE ratio of 16.85, a P/E/G ratio of 0.85 and a beta of 0.73. The company has a current ratio of 3.83, a quick ratio of 3.72 and a debt-to-equity ratio of 1.37. The company’s fifty day simple moving average is $62.71 and its 200-day simple moving average is $53.14.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, topping the Zacks’ consensus estimate of $1.06 by $0.11. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The firm had revenue of $6.01 billion during the quarter, compared to analyst estimates of $5.89 billion. During the same period last year, the company posted $1.09 EPS. The business’s quarterly revenue was up 5.6% compared to the same quarter last year. Equities analysts forecast that Bristol-Myers Squibb Co will post 4.47 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be given a dividend of $0.45 per share. The ex-dividend date of this dividend is Thursday, January 2nd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. This represents a $1.80 dividend on an annualized basis and a yield of 2.68%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 45.23%.

In other news, insider Louis S. Schmukler sold 25,000 shares of Bristol-Myers Squibb stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total transaction of $1,414,000.00. Following the completion of the sale, the insider now directly owns 31,963 shares in the company, valued at approximately $1,807,827.28. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP John E. Elicker sold 15,000 shares of Bristol-Myers Squibb stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total value of $849,900.00. Following the sale, the senior vice president now owns 74,471 shares of the company’s stock, valued at $4,219,526.86. The disclosure for this sale can be found here. Company insiders own 0.13% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Further Reading: What is a stock buyback?

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.